Cantor Fitzgerald initiated coverage of Immatics with an Overweight rating. Immatics features a comprehensive suite of pipeline candidates, platforms, and partnerships centered around directing T cells to solid tumors, and a modest stock valuation makes shares highly attractive, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMTX:
- Immatics initiated with an Overweight at Cantor Fitzgerald
- Immatics receives FDA RMAT designation for IMA203 TCR-T monotherapy
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
- Moderna, Immatics announce strategic multi-platform collaboration
